金色化物Rh4作为一种新型AMPK激活剂,可以预防内皮功能障碍
Jiawei Zhang1, Weiqiang Lv1, Xuyun Liu1
1Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
British journal of pharmacology
|May 17, 2024
概括
金色化物Rh4激活AMP激活蛋白激酶 (AMPK),以防止超脂血症引起的内皮功能障碍. 这种AMPK激活剂在治疗与内皮损伤有关的心血管疾病方面表现有前途.
科学领域:
- 心血管药理学心血管药理学
- 内皮细胞生物学 内皮细胞生物学
- 线粒体医学 线粒体医学
背景情况:
- AMP激活蛋白激酶 (AMPK) 信号传递是心血管疾病 (CVD) 的关键目标.
- 在高脂血症引起的内皮功能障碍中AMPK的机制尚未完全理解.
- 需要新的AMPK激活剂才能进行有效的干预.
研究的目的:
- 确定一个强大的AMPK激活器用于内皮功能障碍.
- 调查已识别的激活剂对高脂血症诱导的内皮功能障碍的疗效和机制.
主要方法:
- 通过分子对接,选罕见的金色化物来激活AMPK.
- 在使用Poloxamer 407 (P407) 的小鼠中诱导的高脂血症.
- 在使用棕酸 (PA) 的人类大动脉内皮细胞 (HAEC) 中诱导的脂质毒性.
主要成果:
- 人参化物Rh4对AMPKα1表现出强烈的结合,并激活了AMPK.
- 在体内和体外,Rh4减弱的内皮损伤和氧化应激.
- Rh4恢复了细胞活力,线粒体功能,并调节了AKT/eNOS,PGC-1α和P38 MAPK/NFκB通路.
- 证实Rh4的影响依赖于AMPK.
结论:
- 金色化物Rh4是一种新型AMPK激活剂,具有对高脂血症引起的内皮功能障碍的保护作用.
- Rh4 具有预防和治疗内皮损伤相关心血管疾病的潜力.
- 这项研究为针对心血管疾病的AMPK向治疗提供了新的机制性见解.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:25cAMP-dependent Protein Kinase Pathways
6.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K